Median Technologies, a world leading oncology clinical trial imaging services provider, becomes preferred vendor to another Top 3 pharmaceutical company.

Press release – For immediate release – 5:45 pm CEST

Median Technologies, a world leading oncology clinical trial imaging services provider, becomes preferred vendor to another Top 3 pharmaceutical company.

• Median Technologies has been selected as a preferred clinical trial imaging services provider for another leading global pharmaceutical company.
• Median Technologies is now preferred provider for two of the Top 3 global pharma companies, based on oncology sales [1].
• The pharmaceutical company has one of the largest clinical trial pipelines in oncology and is a new client for Median.
• The agreement covers late phase oncology trials for which central image readouts are required.
• The new agreement highlights Median’s strength as a leading clinical trial imaging provider in the United States.

Median Technologies (FR0011049824, ALMDT, PEA/PME scheme eligible, “Median” or “The Company”) announced today that the Company has been selected as preferred vendor by a Top 3 pharmaceutical company, adding another one of the largest global pharmaceutical companies to its client portfolio. Median Technologies is now preferred provider for two of the Top 3 pharma companies, based on oncology sales [2].

The Master Service Agreement (MSA) came after an in-depth selection process. The new client has one of the largest oncology pipelines in the world and presents one of the highest R&D to revenue ratios in the pharmaceutical industry [3]. Median will manage central image reads for late phase clinical trials in the client’s oncology pipeline. The MSA is a recognition of Median’s performance, quality, and competitiveness for imaging services worldwide.

Fredrik Brag, CEO and Founder of Median Technologies said: “Median’s’ iCRO services are best-in-class and recognized as such worldwide. The agreement will ensure stable future bookings and revenues growth for Median, while the Top 3 pharmaceutical company will benefit from improved operational execution using the best technology available in the market. Our recognized expertise in AI applied to medical images, has been a strong technology differentiator during the diverse phases of the negotiation; it represents a unique asset compared to the standard offering of our competitors as well as a major trigger for the acceleration of growth opportunities for our Company, in the era of precision medicine.”

Nicolas Dano, COO & CCO iCRO, added: “The new preferred vendor agreement significantly strengthens our position in the United States. It is the result of our investments to deliver top-tier best-in-class imaging services, our commitment to achieving customer satisfaction, and the wealth of experience acquired in supporting sponsors with their regulatory filings. With the combination of our two offerings, iSee® for central image reads, and Imaging Lab, iCRO’s unique AI-powered imaging offering, we cover a very wide and unique spectrum of imaging services for the pharma industry, from standard image reads to advanced imaging services using cutting edge AI-based technologies. We are proud to support the pharma industry in bringing the next generation of life-saving oncology drugs to market”.

[1] Arjun Murthy – Top 15 biopharma companies by Oncology Sales in 2023

[2] Arjun Murthy – Top 15 biopharma companies by Oncology Sales in 2023

[3]Update: April 30, 2024: https://www.drugdiscoverytrends.com/top-pharma-companies-2023-rd-spend/